<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">29763119</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK499944</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2022</Year><Month>01</Month></PubDate><BeginningDate><Year>2022</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-28780">Scleritis</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagina</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Michigan</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramphul</LastName><ForeName>Kamleshun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Shanghai Jiao Tong University</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText>Scleritis is a severe ocular inflammatory condition affecting the sclera, the outer covering of the eye. It can be categorized as anterior with diffuse, nodular, or necrotizing subtypes and posterior with diffuse or nodular subtypes. Scleritis can be visually significant, depending on the severity and presentation and any associated systemic conditions. The presentation can be unilateral or bilateral. </AbstractText><CopyrightInformation>Copyright © 2022, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s6">Histopathology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s7">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s8">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s9">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s10">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s11">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s12">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s13">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s14">Pearls and Other Issues</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s15">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s16">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-28780" sec="article-28780.s17">References</SectionTitle></Section></Sections><ContributionDate><Year>2022</Year><Month>5</Month><Day>2</Day></ContributionDate><ReferenceList><Reference><Citation>Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005 Jul-Aug;50(4):351-63.</Citation><ArticleIdList><ArticleId IdType="pubmed">15967190</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel Diaz J, Sobol EK, Gritz DC. Treatment and management of scleral disorders. Surv Ophthalmol. 2016 Nov - Dec;61(6):702-717.</Citation><ArticleIdList><ArticleId IdType="pubmed">27318032</ArticleId></ArticleIdList></Reference><Reference><Citation>Artifoni M, Rothschild PR, Brézin A, Guillevin L, Puéchal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014 Feb;10(2):108-16.</Citation><ArticleIdList><ArticleId IdType="pubmed">24323074</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims J. Scleritis: presentations, disease associations and management. Postgrad Med J. 2012 Dec;88(1046):713-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22977282</ArticleId></ArticleIdList></Reference><Reference><Citation>Oray M, Meese H, Foster CS. Diagnosis and management of non-infectious immune-mediated scleritis: current status and future prospects. Expert Rev Clin Immunol. 2016 Aug;12(8):827-37.</Citation><ArticleIdList><ArticleId IdType="pubmed">27055583</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieringa WG, Wieringa JE, ten Dam-van Loon NH, Los LI. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013 Feb;120(2):379-86.</Citation><ArticleIdList><ArticleId IdType="pubmed">23177360</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29763119</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>
